Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the US, 2015-2025.
- DOI
- 10.1215/03616878-12513812
- Published
- 2026 Oct 1
- Container
- Journal of health politics, policy and law
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1215/03616878-12513812,
title = {Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the US, 2015-2025.},
author = {Drake K and Conti R},
year = {2026},
journal = {Journal of health politics, policy and law},
doi = {10.1215/03616878-12513812},
url = {https://doi.org/10.1215/03616878-12513812}
}RIS
TY - JOUR TI - Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the US, 2015-2025. AU - Drake K AU - Conti R PY - 2026 JO - Journal of health politics, policy and law DO - 10.1215/03616878-12513812 UR - https://doi.org/10.1215/03616878-12513812 ER -
APA
K, D., & R, C. (2026). Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the US, 2015-2025.. Journal of health politics, policy and law. https://doi.org/10.1215/03616878-12513812
Source records
- pubmed · retrieved 2026-11-10T15:04:20.763Z
- europe-pmc · retrieved 2026-11-10T15:04:20.770Z